Antiproliferatives and Transplantation

Area of Science:

• Immunosuppression
• Pharmacology
• Transplant Medicine

Background:

• Antiproliferative agents, including Mycophenolic acid and Azathioprine, were initially studied for autoimmune diseases and cancer.
• Their mechanism involves disrupting cellular replication, making them valuable in research.
• These agents have become fundamental in preventing organ rejection after transplantation.

Purpose of the Study:

• To detail the discovery timeline of key antiproliferative agents.
• To elucidate their mechanisms of action, side effects, and use in pregnancy.
• To review significant clinical trials involving these immunosuppressants.

Main Methods:

• Literature review of historical discoveries.
• Analysis of pharmacological mechanisms of action.
• Synthesis of data from major clinical trials.

Main Results:

• Mycophenolic acid and Azathioprine are established as vital for solid organ transplant antirejection therapy.
• Their efficacy in preventing rejection is supported by extensive clinical data.
• Understanding their side effect profiles and use in specific populations, like pregnant individuals, is crucial.

Conclusions:

• Antiproliferative agents are indispensable in modern transplant care.
• Continued research and clinical trials refine their application and safety.
• These drugs highlight the successful translation of cancer research into life-saving transplant therapies.